STOCK TITAN

Co-Diagnostics (CODX) 424B Filings

CODX NASDAQ

Here are the 424B prospectus supplements from Co-Diagnostics, Inc. (CODX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.

Rhea-AI Summary

Co-Diagnostics, Inc. is establishing an at-the-market equity program to sell up to $7,901,383 of common stock under an Equity Distribution Agreement with Maxim Group LLC. Maxim will act as sales agent, earning a 3% commission on gross proceeds from any shares sold.

Common stock outstanding was 5,278,957 shares as of June 30, 2026, and could rise to up to 9,040,409 shares if 3,762,563 shares are sold at $2.10 per share. The company intends to use any net proceeds primarily for working capital and general corporate purposes.

The company qualifies as a smaller reporting company, has a recent going concern explanatory paragraph from its auditor, and highlights risks including potential dilution, Nasdaq Capital Market listing compliance (including a $1.00 minimum bid monitor through March 9, 2027), and variability in pricing under the ATM program.